Human miRNome profiling identifies microRNAs differentially present in the urine after kidney injury

Clinical Chemistry

Volumn 59, Issue 12, 2013, Pages 1742-1752

  Ramachandran, Krithika ^a   Saikumar, Janani ^a   Bijol, Vanesa ^b   Koyner, Jay L ^c   Qian, Jing ^d   Betensky, Rebecca A ^e   Waikar, Sushrut S ^a   Vaidya, Vishal S ^a,f  

^a Renal Division   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e Division of Biostatistics   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KIDNEY INJURY MOLECULE 1; MICRORNA;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN TISSUE; INTENSIVE CARE UNIT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LABORATORY DEVICE; MAJOR CLINICAL STUDY; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE DIPSTICK ANALYSIS; VALIDATION STUDY;

ACUTE KIDNEY INJURY; COHORT STUDIES; CROSS-SECTIONAL STUDIES; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS;

EID: 84889825012     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.210245     Document Type: Article

References (39)

1. Li PK, Burdmann EA, Mehta RL. Acute kidney injury: global health alert. Kidney Int 2013;83: 372-6.
2. Star RA. Treatment of acute renal failure. Kidney Int 1998;54:1817-31.
3. Koyner JL, Parikh CR. Clinical utility of biomarkers of AKI in cardiac surgery and critical illness. Clin J Am Soc Nephrol 2013;8:1034-42.
4. Ho J, Dart A, Rigatto C. Proteomics in acute kidney injury - current status and future promise. Pediatr Nephrol 2013 Apr 18. http://link.springer. com/article/10.1007%2Fs00467-013-2415-x (Accessed October 2013).
5. Jensen ON. Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. Curr Opin Chem Biol 2004;8:33-41.
6. Bonventre JV. Diagnosis of acute kidney injury: from classic parameters to new biomarkers. Contrib Nephrol 2007;156:213-9.
7. Dennen P, Parikh CR. Biomarkers of acute kidney injury: Can we replace serum creatinine? Clin Nephrol 2007;68:269-78.
8. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 2008; 9:219-30.
9. Erson AE, Petty EM. MicroRNAs in development and disease. Clin Genet 2008;74:296 -306.
10. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010;56:1733-41.
11. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105:10513- 8.
12. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58:1375-81.
13. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009;10:42-6.
14. Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N. Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 2009;55:1944 -9.
15. Yang X, Greenhaw J, Shi Q, Su Z, Qian F, Davis K, et al. Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity. Toxicol Sci 2012;125:335-44.
16. Argyropoulos C, Wang K, McClarty S, Huang D, Bernardo J, Ellis D, et al. Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLoS One 2013;8:e54662.
17. Lorenzen JM, Volkmann I, Fiedler J, Schmidt M, Scheffner I, Haller H, et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am J Transplant 2011; 11:2221-7.
18. Saikumar J, Hoffmann D, Kim TM, Gonzalez VR, Zhang Q, Goering PL, et al. Expression, circulation, and excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol Sci 2012;129:256-67.
19. Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 2010;28:478-85.
20. Vaidya VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules C, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci 2008;1: 200-8.
21. Hsu R, McCulloch C, Dudley R, Lo L, Hsu CY. Temporal changes in incidence of dialysisrequiring AKI. J Am Soc Nephrol 2013;24:37-42.
22. Bonventre JV, Vaidya VS, Schmouder R, Feig P, Dieterle F. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010;28: 436-40.
23. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008;48:463-93.
24. Lorenzen JM, Kielstein JT, Hafer C, Gupta SK, Kumpers P, Faulhaber-Walter R, et al. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 2011;6:1540-6.
25. Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol 2011;8:706-13.
26. Liang H, Zhang C, Ban T, Liu Y, Mei L, Piao X, et al. A novel reciprocal loop between microRNA-21 and TGFβRIII is involved in cardiac fibrosis. Int J Biochem Cell Biol 2012;44:2152-60.
27. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010;207:1589 -97.
28. Chau BN, Xin C, Hartner J, Ren S, Castano AP, Linn G, et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 2012;4:121ra18.
29. Peter ME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 2009;8:843-52.
30. Ali S, Almhanna K, Chen W, Philip PA, Sarkar FH. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res 2010;3:28-47.
31. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110:13-21.
32. Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 2012;14:147-54.
33. Oak SR, Murray L, Herath A, Sleeman M, Anderson I, Joshi AD, et al. A microRNA processing defect in rapidly progressing idiopathic pulmonary fibrosis. PLoS One 2011;6:e21253.
34. Te JL, Dozmorov IM, Guthridge JM, Nguyen KL, Cavett JW, Kelly JA, et al. Identification of unique microRNA signature associated with lupus nephritis. PLoS One 2010;5:e10344.
35. Bhattacharyya M, Bandyopadhyay S. Studying the differential co-expression of microRNAs reveals significant role of white matter in early Alzheimer's progression. Mol Biosyst 2013;9:457-66.
36. Persson H, Kvist A, Rego N, Staaf J, Vallon- Christersson J, Luts L, et al. Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res 2011;71:78-86.
37. Neal CS, Michael MZ, Pimlott LK, Yong TY, Li JY, Gleadle JM. Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant 2011;26:3794-802.
38. Zhong X, Chung AC, Chen HY, Meng XM, Lan HY. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 2011;22: 1668-81.
39. Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, et al. The small- ucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer 2011;104:1168-77.